Home › Research › Mild cognitive impairment
The analysis of the gut microbiome during liver disease progression led to the identification of biomarkers for related mild cognitive impairment
Lola Giner-Pérez, Juan Gallego, Carla Giménez‐Garzó, Daniela Batallas, Víctor Hugo Jarquín‐Díaz, Franc Casanova‐Ferrer, Alessandra Fiorillo, Amparo Urios et al.. Frontiers in Microbiology, 2025-09-16
Topic: Brain proteins, microglia and lab models
Plain-language summary
could serve as potential biomarkers for NAFLD-associated mild cognitive impairment; 3) bacterial metabolic functions involved in sugar degradation and the breakdown of tryptophan and glutamate were downregulated and linked to CXCL13 plasma levels and neuroinflammation; 4) correlations between SCFA concentrations disappeared with liver disease and cognitive impairment. In this context, maintaining a balanced production of fecal SCFA is more important than individual concentrations. The downregulation of specific microbial metabolic pathways, along with the presence of certain bacterial species, holds promise as early-stage biomarkers and highlights the potential of microbiome-targeted strategies for monitoring and managing liver-related cognitive impairment.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Giner-Pérez, L., Gallego, J., Giménez‐Garzó, C., Batallas, D., Jarquín‐Díaz, V. H., Casanova‐Ferrer, F., et al. (2025). The analysis of the gut microbiome during liver disease progression led to the identification of biomarkers for related mild cognitive impairment. Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2025.1670512
Vancouver
Giner-Pérez L, Gallego J, Giménez‐Garzó C, Batallas D, Jarquín‐Díaz VH, Casanova‐Ferrer F, et al. The analysis of the gut microbiome during liver disease progression led to the identification of biomarkers for related mild cognitive impairment. Frontiers in Microbiology. 2025. doi:10.3389/fmicb.2025.1670512. PMID: 41035890.
BibTeX
@article{ginerperez2025-41035890,
author = {Giner-Pérez, Lola and Gallego, Juan and Giménez‐Garzó, Carla and Batallas, Daniela and Jarquín‐Díaz, Víctor Hugo and Casanova‐Ferrer, Franc and Fiorillo, Alessandra and Urios, Amparo and others},
title = {{The analysis of the gut microbiome during liver disease progression led to the identification of biomarkers for related mild cognitive impairment}},
journal = {Frontiers in Microbiology},
year = {2025},
doi = {10.3389/fmicb.2025.1670512},
pmid = {41035890},
url = {https://doi.org/10.3389/fmicb.2025.1670512}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- could serve as potential biomarkers for NAFLD-associated mild cognitive impairment; 3) bacterial metabolic functions involved in sugar degradation and the breakdown of tryptophan and glutamate were downregulated and linked to CXCL13 plasma levels and neuroinflammation; 4) correlations between SCFA concentrations disappeared with liver disease and cognitive impairment.
- In this context, maintaining a balanced production of fecal SCFA is more important than individual concentrations.
- The downregulation of specific microbial metabolic pathways, along with the presence of certain bacterial species, holds promise as early-stage biomarkers and highlights the potential of microbiome-targeted strategies for monitoring and managing liver-related cognitive impairment.
Why it matters
This study identified gut microbiome features and bacterial metabolic pathways as potential biomarkers for mild cognitive impairment associated with non-alcoholic fatty liver disease. It is a biomarker study and does not test any treatment, cure or prevention.
Study details
- Evidence strengthLow
How this study scored 40/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 38 of the 96 points we could judge it on, which is 40 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Frontiers in Microbiology) |
| Journal's citation record | 3 / 4 | Frontiers in Microbiology: journal h-index 345 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 4 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 1.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 4 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 1 / 3 | Charité - Universitätsmedizin Berlin: institution h-index 1,116 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 12 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41035890) |
| Free to read | 2 / 2 | Free to read |
| Points | 38 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 38 of the 96 points we could judge it on is 40 out of 100. |
| Total | 40 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.3389/fmicb.2025.1670512
- PubMed: 41035890
- Original source →
- Free full text: Frontiers in Microbiology →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Mild cognitive impairment from nearby years
Also tagged “mini-mental”
840 studies in the library carry the topic tag “mini-mental”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 840 tagged studies.